Interview With Spencer Hawkswell

Today’s episode for you focuses on why C-O FOUNDER and CEO JR Rahn founded Mindmed and on Reconstructing how we treat mental health in America.

MindMed, (MMED) on the Canadian NEO Stock exchange and (MMEDF) on the American Over the counter market has been experiencing a pull back lately. Remember what I said before: MindMed should be looked as a long term investment and is not for investors with weak stomachs!

During his recent appearance on Context 360 with Kevin O’Leary, MindMed’s Co-Ceo Jr Rahn made a sober prediction that the mental health crisis will only get worse.
-automation, sped up by the Rona virus, will depend our crisis of identity, and cause millions more to suffer. If we do nothing now, soon we could be living in a very dark world
-to reiterate a couple alarming stats; 40% have has a mental health incident or have addiction and 11% have considered committing suicide. This is terrifying, and only going to get worse. MindMed was founded with the vision to find a solution or rather multiple solutions to these mental problems. If successful, the company stands to take the biotech industry by storm and we, as psychedelic investors, will reap the returns.

https://www.youtube.com/watch?v=mNfq6eEUT7Q&t=459s&ab_channel=ContextLive

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Numinus Acquiring Novamind in First Major Psychedelics Merger

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Not only will this be your chance to meet me, but also the legendary Paul Stamets!

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Back to Numinus

This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.

Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).

The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.

If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.

#Numinus #NovaMind #psychedelicStocks